Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00248261
Status:
TERMINATED
Last Update Posted:
2020-02-25
First Post:
2005-11-02
Brief Title:
Ziprasidone and Sertraline in PTSD
Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Organization:
Universitätsklinikum Hamburg-Eppendorf
Study Overview
Official Title:
Effects of Ziprasidone vs Placebo During the First Four Weeks of Eight Weeks Sertraline Treatment in Patients With Post-traumatic Stress Disorder PTSD
Status:
TERMINATED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
High rate of early drop-outs
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Serotonin re-uptake inhibitors such as sertraline are the medication of choice in post-traumatic stress disorder However it takes several weeks before they ameliorate symptoms Therefore we will add ziprasidone vs placebo medication during the first four weeks of sertraline in order to find out if this strategy accelerates symptomatic relief
Detailed Description:
A current problem in the pharmacotherapy of PTSD is that the medication of choice serotonin re-uptake inhibitors take several weeks before they show considerable effects on PTSD symptoms Addition of typical neuroleptics such as ziprasidone offers a potential strategy to bring about a faster symptomatic relief because they display anxiolytic properties without the risk of dependence Therefore in addition to standard sertraline therapy at least 8 weeks we will give ziprasidone vs placebo over the first four weeks in a double-blind randomized design
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NRA1280017 | None | None | None |